Shuttle Pharmaceuticals Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Shuttle Pharmaceuticals Holdings, Inc. | |||
| By: | /s/ Christopher Cooper | ||
| Christopher Cooper | |||
| Interim Chief Executive Officer | |||
| Date: | March 31, 2026 | Principal Executive Officer | |
|---|---|---|---|
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Christopher Cooper | Chairman of the board of directors, | |
| Christopher Cooper | Interim Chief Executive Officer | March 31, 2026 |
| (principal executive officer) | ||
| /s/ Yuying Liang | Chief Financial Officer | |
| Yuying Liang | (principal financial and accounting officer) | March 31, 2026 |
| /s/ George Scorsis | Director | |
| George Scorsis | March 31, 2026 | |
| /s/ Adam Chambers | Director | |
| Adam Chambers | March 31, 2026 | |
| /s/ Angel Liriano | Director | |
| Angel Liriano | March 31, 2026 | |
| /s/ Oleh Nabyt | Director | |
| Oleh Nabyt | March 31, 2026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.